Skip to content
    Amzak Health logo

    Amzak Health

    New York, New York, United StatesFounded 2015

    Amzak Health is an evergreen healthcare investment fund and the healthcare investment arm of Amzak Capital Management, the private investment firm of the Kazma family. Based in New York City, the firm invests in first-in-class and best-in-class medtech and biotech companies, supporting portfolio companies throughout their lifecycle from early-stage through commercialization.

    Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-a (40% of deals). Average disclosed round size is $57.2M (across 15 rounds with reported amounts).

    Find people at Amzak Health on Goldilocks AI

    Portfolio

    11

    Fund Size

    Top Stage

    Series A

    Last 12 Mo

    0

    Team

    JE

    Joyce Erony

    Managing Partner

    TN

    Tony Natale

    Partner

    DS

    Dave Siet

    Principal

    MC

    Margarita C. Bernard

    Operations Manager

    SW

    Scott Weiner

    Partner

    DS

    David Siet

    Healthcare investor

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    15 investments
    CompanyRoundAmountDate
    Neuros Medical logoNeuros MedicalSeries D$56MJul 2025
    Neuros logoNeurosSeries D$56MJul 2025
    SSound Blade MedicalSeries A$16.5MJan 2025
    Neuros logoNeurosUnknown$56MJan 2025
    SSynergy Spine SolutionsSeries A$30MJan 2024
    ShiraTronics, Inc logoShiraTronics, IncSeries B$66MJan 2024
    SSynergy SpineSeries A$30MJan 2024
    ShiraTronics, Inc logoShiraTronics, IncSeries A$3MJan 2023
    Antios Therapeutics logoAntios TherapeuticsSeries B$75MNov 2021
    AAntios Therapeutics, Inc.Series A$75MNov 2021
    AAntios Therapeutics, Inc.Series B$96MApr 2021
    AAntios Therapeutics, Inc.Series B$96MJan 2021
    RReneo Pharmaceuticals IncSeries B$95MDec 2020
    44DMTSeries C$75MJun 2020
    Shiratronics logoShiratronicsSeries A$33MOct 2019

    Top Co-Investors

    Last updated: 8 September 2026